SCHEMBL426697

SCHEMBL426697

CN(C(=O)n1cnc(-c2ccccc2F)c1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
USP19 O94966 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CCKAR P32238 1/20 0.38
CCKBR P32239 1/20 0.38
GRIN2B Q13224 4/20 0.38
POLB P06746 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
ADORA2A P29274 3/20 0.37
ADORA3 P0DMS8 2/20 0.37
ADORA1 P30542 2/20 0.37
ADORA2B P29275 1/20 0.37
MLNR O43193 1/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
TACR3 P29371 1/20 0.36
LTB4R Q15722 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427489 0.93 FAAH (0.40) FAAHSMN1; SMN2USP19KDM4EGRIN2B
SCHEMBL425371 0.84 FAAH (0.60) FAAHSMN1; SMN2KDM4ELMNATP53
SCHEMBL425550 0.83 FAAH (0.51) FAAHSMN1; SMN2KDM4ELMNATP53
SCHEMBL427476 0.81 FAAH (0.57) FAAHSMN1; SMN2KDM4ELMNATP53
SCHEMBL426698 0.79 FAAH (0.52) FAAHSMN1; SMN2KDM4EPOLBLMNA
SCHEMBL425400 0.78 FAAH (0.54) FAAHSMN1; SMN2LMNAMAPT
SCHEMBL426994 0.78 FAAH (0.51) FAAHSMN1; SMN2KDM4ELMNATP53
SCHEMBL16212908 0.77 USP19 (0.45) USP19GRIN2BPOLBADORA2AADORA3
SCHEMBL425420 0.76 FAAH (0.52) FAAHSMN1; SMN2KDM4E
SCHEMBL426694 0.76 ACHE (0.49) FAAHSMN1; SMN2KDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885SMN1; SMN2 2818/4885USP19 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.